Establishing a nurse-led system to administer tocilizumab in patients receiving bispecific antibodies tended to get the immunosuppressive drug to patients faster.

Fresenius, via its operating company Fresenius Kabi, is introducing Tyenne (tocilizumab-aazg), a biosimilar of Actemra ...

The Swiss pharmaceutical company reiterated its outlook, predicting single-digit growth this year, following an end to the ...

A new meta-analysis of chimeric antigen receptor (CAR) T-cell therapy in patients with multiple myeloma (MM) suggests the ...

On April 15, 2024, Fresenius Kabi announced the U.S. launch of its ACTEMRA biosimilar, TYENNE (tocilizumab-aazg) as an intravenous formulation. As we previously reported, Fresenius Kabi received FDA ...

Medically reviewed by Geetika Gupta, MD Having a low white blood cell (WBC) count, also known as leukopenia, means that your ...

Cytokine release syndrome (CRS) occurs when the immune system responds to infection or immunotherapy drugs more aggressively ...

Higher CCL24 levels in systemic sclerosis patients have been linked to more severe forms of the condition. Clinical-stage ...

Fresenius Kabi announced that Tyenne® (tocilizumab-aazg), a biosimilar of Actemra® (tocilizumab) is now available in the U.S.

South Korea’s Celltrion has presented positive two-year results from the extended LIBERTY studies (LIBERTY-CD1 and LIBERTY-UC2) of subcutaneous (SC) infliximab in patients with moderately to severely ...

Roche's (RHHBY) performance in first-quarter 2024 is pretty ho-hum as COVID-19-test sales continue to decline. The top line ...

For patients with lymphoma or multiple myeloma, speaking up about symptoms of cytokine release syndrome can be lifesaving.